{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=7", "query": { "condition": "Amplification", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 148, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T08:43:41.089Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02186821", "title": "Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumors With Aberrations in ALK or ROS1" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2014-09-17", "completion_date": "2017-12-13", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 21, "location_summary": "Santa Rosa, California • Denver, Colorado • Greenwood Village, Colorado + 17 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186821" }, { "nct_id": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": "2021-07-15", "completion_date": "2024-07-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985604" }, { "nct_id": "NCT06995677", "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low-grade NMIBC", "FGFR Gene Amplification", "FGFR Gene Alterations", "FGFR3 Gene Alteration", "FGFR3 Gene Mutation", "FGFR3 Gene Fusions" ], "interventions": [ { "name": "TYRA-300 60mg", "type": "DRUG" }, { "name": "TYRA-300 50mg", "type": "DRUG" }, { "name": "TYRA-300 Dose 70 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-06-27", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 36, "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995677" }, { "nct_id": "NCT00620984", "title": "Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mastitis", "Staphylococcus Aureus", "Staphylococcal Infections" ], "interventions": [], "intervention_types": [], "sponsor": "State University of New York - Upstate Medical University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 557, "start_date": "2006-08", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2015-06-02", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00620984" }, { "nct_id": "NCT02609776", "title": "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 751, "start_date": "2016-05-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 17, "location_summary": "Duarte, California • La Jolla, California • Orange, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02609776" }, { "nct_id": "NCT01613950", "title": "PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein" ], "interventions": [ { "name": "AUY922", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-12", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613950" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" }, { "nct_id": "NCT04074785", "title": "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "GBM", "Glioblastoma", "Brain Tumor", "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2019-12-13", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04074785" }, { "nct_id": "NCT06264921", "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Cancer", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2024-02-23", "completion_date": "2025-04-16", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264921" }, { "nct_id": "NCT02867774", "title": "Impact of Physical Activity for Chronic Pelvic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pelvic Pain" ], "interventions": [ { "name": "Physical Activity", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 22, "start_date": "2016-08", "completion_date": "2017-12-28", "has_results": false, "last_update_posted_date": "2018-03-01", "last_synced_at": "2026-10-23T08:43:41.089Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02867774" } ] }